EP3000810A1 — N3 alkylated benzimidazole derivative as mek inhibitor
Assigned to Array Biopharma Inc · Expires 2016-03-30 · 10y expired
What this patent protects
Pharmaceutical compositions comprising a compound of the formula I selected from 6-(4-bromo-2-fluoro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof, for use in the treatment of hype…
USPTO Abstract
Pharmaceutical compositions comprising a compound of the formula I selected from 6-(4-bromo-2-fluoro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and pharmaceutically acceptable salts thereof, for use in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.